EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

[Impact of the Subcutaneous Formulation of Daratumumab in the Treatment of Multiple Myeloma: pharmacoeconomic aspects of the new formulation]

Cristina Pittella

Farmeconomia. Health Economics and Therapeutic Pathways · 18.11.2026 · 27 (1) · 81-90

DOI: 10.7175/fe.v27i1.1615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Farmeconomia. Health Economics and Therapeutic Pathways, online erschienen am 18.11.2026. Verfasst von Cristina Pittella. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The subcutaneous (SC) formulation of daratumumab substantially shortens administration time compared with the intravenous (IV) formulation and may improve organizational efficiency and reduce treatment-related resource use in hematology units. This study aimed to compare administration-related costs of SC and IV daratumumab at the Hematology Unit of ARNAS Garibaldi Hospital in Catania, Italy. METHODS: A microcosting analysis adapted Federici et al.'s methodology to the local setting. Published discrete event simulation scenarios from the same study were used to contextualize the potential organizational implications of SC versus IV administration. The analysis included healthcare professional time, preparation and administration materials, drug transport from the centralized antineoplastic drug unit to the day hospital, and healthcare waste disposal. Organizational and time parameters were replaced, whenever available, with 2025 real-world data from the study center. RESULTS: In 2025, 118 patients with multiple myeloma were treated at the center, including 88 receiving daratumumab, of whom 86 received the SC formulation and were considered in this analysis. Mean body weight was 74.9 kg. Overall, 850 SC administrations were performed: 26 first, 26 second, and 798 subsequent administrations. Administration time was 5 minutes for SC daratumumab, and 420 minutes for the first IV infusion and 300 minutes for subsequent infusions. Administration-related costs for SC totaled €16,048.00. In the counterfactual IV scenario, estimated costs would have been €64,376.58, corresponding to estimated savings of €48,328.58. Following the introduction of SC daratumumab in 2024, treated patients increased from 36 to 93 and remained broadly stable at 88 in 2025. CONCLUSIONS: In this single-center analysis, SC daratumumab was associated with shorter administration times and lower organizational resource use, with the model estimating substantial savings in administration-related costs and a potential increase in treatment capacity. Because the comparison relied on a modeled counterfactual scenario, these findings should be confirmed in additional healthcare settings.

Zitieren

APA

Pittella, C. (2026). [Impact of the Subcutaneous Formulation of Daratumumab in the Treatment of Multiple Myeloma: pharmacoeconomic aspects of the new formulation]. Farmeconomia. Health Economics and Therapeutic Pathways, 27(1), 81-90. https://doi.org/10.7175/fe.v27i1.1615

Vancouver

Pittella C. [Impact of the Subcutaneous Formulation of Daratumumab in the Treatment of Multiple Myeloma: pharmacoeconomic aspects of the new formulation]. Farmeconomia. Health Economics and Therapeutic Pathways. 2026;27(1):81-90. doi:10.7175/fe.v27i1.1615

BibTeX
@article{Pittella2026,
  author = {Pittella, Cristina},
  title = {[Impact of the Subcutaneous Formulation of Daratumumab in the Treatment of Multiple Myeloma: pharmacoeconomic aspects of the new formulation]},
  journal = {Farmeconomia. Health Economics and Therapeutic Pathways},
  year = {2026},
  volume = {27},
  number = {1},
  pages = {81--90},
  doi = {10.7175/fe.v27i1.1615}
}
Kostenlos starten →